Tests cadonilimab with chemotherapy before surgery for advanced cervical cancer
Tests cadonilimab with chemotherapy before surgery in adults with locally advanced cervical cancer.
Plain-language title generated from the registry record
Registry title: Cadonilimab Plus Chemotherapy in LACC: A Prospective, Multicenter, Randomized Phase II Trial
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07649174, who can take part
Where in China
- Obstetrics and Gynecology Hospital of Fudan UniversityShanghai, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Obstetrics & Gynecology Hospital of Fudan University
- Trial code
- NCT07649174
- Record updated
- 16 June 2026
- Original description
This is a prospective, multi-center, randomized controlled phase II clinical trial aimed at exploring the efficacy evaluation of cadilonilumab immunotherapy combined with chemotherapy for locally advanced cervical cancer.Read full original descriptionShow less
Efficacy of Cadonilimab in Combination With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Cervical Cancer: A Prospective, Multicenter, Randomized Phase II Trial
This is a prospective, multi-center, randomized controlled phase II clinical trial aimed at exploring the efficacy evaluation of cadilonilumab immunotherapy combined with chemotherapy for locally advanced cervical cancer.
Inclusion: Patients with previously untreated locally advanced cervical cancer, clinically staged as FIGO 2018 stage IB3, IIA2, IIB, or IIIC1r (tumor diameter >4 cm as assessed by contrast-enhanced pelvic MRI); Histologically or cytologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma; Female patients aged ≥18 and ≤75 years; Willing and able to provide written informed consent and comply with study visits and protocol-required procedures; Eligible for radical hysterectomy with curative intent; At least one measurable lesion according to RECIST version 1.1; Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; Estimated life expectancy of at least 6 months; Women of childbearing potential must agree to use effective contraception throughout the study period. A negative serum or urine pregnancy test is required before study enrollment.
Exclusion: Active malignancy within 3 years prior to enrollment (with specified exceptions); Prior exposure to immune checkpoint inhibitors or other immunomodulatory anticancer therapies; Major surgery within 4 weeks before study treatment; Unresolved toxicities from previous anticancer therapy (> Grade 1, CTCAE v5.0); CNS metastases or leptomeningeal disease; Severe cardiovascular or cerebrovascular disease; Known hypersensitivity to study drugs; Serious medical or psychiatric conditions that may interfere with study participation; Histological subtypes other than squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma, including but not limited to small cell carcinoma and clear cell carcinoma; Clinically significant unrecoverable hydronephrosis; Pregnancy.